Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M, Bortesi B, Goldoni M, Silini EM, De Palma G, Mutti A, Ardizzoni A.

Lung Cancer. 2014 Feb;83(2):265-71. doi: 10.1016/j.lungcan.2013.12.001. Epub 2013 Dec 12.

PMID:
24388705
[PubMed - in process]
3.

Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.

Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C.

Respirology. 2009 Jul;14(5):709-15. doi: 10.1111/j.1440-1843.2009.01564.x.

PMID:
19659649
[PubMed - indexed for MEDLINE]
4.

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui K, Katsura T.

Clin Pharmacokinet. 2013 Jul;52(7):593-609. doi: 10.1007/s40262-013-0058-5.

PMID:
23532985
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.

Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.

PMID:
22277837
[PubMed - indexed for MEDLINE]
6.

Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.

Boyer M, Horwood K, Pavlakis N, De Souza P, Millward M, Stein B, Johnston M, Abell F, Rischin D.

Asia Pac J Clin Oncol. 2012 Sep;8(3):248-54. doi: 10.1111/j.1743-7563.2012.01540.x. Epub 2012 May 15.

PMID:
22898114
[PubMed - indexed for MEDLINE]
7.

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C.

Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.

PMID:
21783417
[PubMed - indexed for MEDLINE]
8.

[Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer.].

Huang Y, Yang J, Huang Y, Xu C, Zhou Q, Wang Z, Wu Y.

Zhongguo Fei Ai Za Zhi. 2009 May 20;12(5):412-6. doi: 10.3779/j.issn.1009-3419.2009.05.019. Chinese.

PMID:
20719136
[PubMed]
Free Article
9.

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.

Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A.

Lung Cancer. 2009 May;64(2):199-206. doi: 10.1016/j.lungcan.2008.09.001. Epub 2008 Oct 31.

PMID:
18951651
[PubMed - indexed for MEDLINE]
10.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.

Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N.

J Thorac Oncol. 2008 Dec;3(12):1439-45. doi: 10.1097/JTO.0b013e31818d6702.

PMID:
19057270
[PubMed - indexed for MEDLINE]
12.

Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.

Binder D, Buckendahl AC, Hübner RH, Schlattmann P, Temmesfeld-Wollbrück B, Beinert T, Suttorp N.

Med Oncol. 2012 Mar;29(1):193-8. doi: 10.1007/s12032-010-9767-x. Epub 2010 Dec 14.

PMID:
21327738
[PubMed - indexed for MEDLINE]
13.

Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.

Motoshima K, Nakamura Y, Sano K, Ikegami Y, Ikeda T, Mizoguchi K, Takemoto S, Fukuda M, Nagashima S, Iida T, Tsukamoto K, Kohno S.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1299-1304.

PMID:
24121455
[PubMed - indexed for MEDLINE]
14.

Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.

Smith J.

Clin Ther. 2005 Oct;27(10):1513-34. Review.

PMID:
16330289
[PubMed - indexed for MEDLINE]
15.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C.

Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.

PMID:
23078958
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.

Kiyohara Y, Yamazaki N, Kishi A.

J Am Acad Dermatol. 2013 Sep;69(3):463-72. doi: 10.1016/j.jaad.2013.02.025. Epub 2013 Apr 17. Review.

PMID:
23602600
[PubMed - indexed for MEDLINE]
Free Article
17.

Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.

Ramsey SD, Clarke L, Kamath TV, Lubeck D.

J Manag Care Pharm. 2006 Jul-Aug;12(6):472-8.

PMID:
16925455
[PubMed - indexed for MEDLINE]
Free Article
18.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
[PubMed - indexed for MEDLINE]
19.

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators.

Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.

PMID:
20493771
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).

Tran HT, Zinner RG, Blumenschein GR Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS.

Invest New Drugs. 2011 Jun;29(3):499-505. doi: 10.1007/s10637-009-9380-z. Epub 2010 Jan 22.

PMID:
20094773
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk